Long-Term Safety of Baricitinib in Pediatric Patients With Atopic Dermatitis Aged 2 to <18 Years With Up to 5.2 Years of Exposure
Abstract
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently begins in childhood and can significantly impact quality of life. Baricitinib, an oral selective Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in pediatric patients with moderate-to-severe AD in short- and intermediate-term analyses.1,2 However, comprehensive long-term safety data remain limited. This final analysis of BREEZE-AD-PEDS reports long-term safety data from pediatric patients treated with baricitinib for up to 5.2 years. Methods: BREEZE-AD-PEDS (NCT03952559) was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The study design included a long-term extension treatment period to evaluate longer-term safety in baricitinib-treated pediatric patients (aged 2 to <18 years) with moderate-to-severe AD. Safety analyses were conducted in the All-BARI population (all patients who received ≥1 dose of baricitinib) and the Extended BARI population (patients randomly assigned to placebo or to 1-mg, 2-mg, or 4-mg baricitinib dose equivalents in the double-blind period who received ≥1 dose of study treatment; censored at transition to open-label baricitinib for non-responders or patients who lost response). Safety outcomes were summarized descriptively and included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESI), laboratory abnormalities, and growth parameters. Incidence rates (IRs) are reported per 100 patient-years at risk. Results: A total of 474 pediatric patients were exposed to baricitinib, corresponding to 1424.5 patient-years of exposure. Median and maximum duration of exposure to baricitinib were 3.3 and 5.2 years, respectively. The majority of patients experienced TEAEs that were mild-moderate in severity. The most frequently reported TEAEs included COVID-19 (IR 8.4), nasopharyngitis (IR 7.2), and upper respiratory tract infection (IR 5.1). Acne occurred exclusively as mild or moderate events (IR 3.7 and 1.0 respectively); no severe acne cases occurred. SAEs and study drug discontinuations due to adverse events occurred at IRs of 3.8 and 1.4, respectively. In All-BARI, 8 patients reported infections that led to study drug discontinuation (IR 0.6). The IR for serious infections was 1.5 (n = 21). Herpes zoster was reported in 14 patients (IR 1.0). No dose-related trends were observed for TEAEs, discontinuations, serious infections, or herpes zoster in Extended BARI (median exposure 17-40 weeks by dose, versus 173 weeks in All-BARI); dose-related increases in total and LDL cholesterol were observed. No deaths, major adverse cardiovascular events, venous thromboembolic events, arterial thrombotic events, malignancies, tuberculosis, or gastrointestinal perforations were reported. Growth parameters, including height, weight, and BMI percentiles, remained broadly consistent with the expected trajectory for a pediatric population throughout the study. The difference between chronological age and radiographic bone age remained consistent through Week 220, with no clinically meaningful changes observed. Conclusion: In this final analysis of the BREEZE-AD-PEDS study, encompassing 1424.5 patient-years and up to 5.2 years of exposure, baricitinib’s long-term safety profile in children remained consistent with previous reports,1,2 with no new safety signals identified. No clinically meaningful impact on growth or bone maturation was observed through Week 220, supporting the long-term use of baricitinib in pediatric patients with moderate-to-severe AD who require systemic therapy.